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was comparable in both groups (7.3% ± 1.3). In G2, the number
of patients reaching HbA1c < 7% was higher by 11.6%. CON-
CLUSION: PwT2D have a “DEFICIT” in knowledge regarding
insulin in general. On an individual basis, PwT2D often under-
estimate the severity of their diabetes. Higher level of knowledge
is correlated with higher WUI and leads to better glycemic
control.
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OBJECTIVES: The study compared patterns of blood glucose
monitoring among patients with type-2 diabetes initiating
therapy with insulin or oral medication and examined the rela-
tionship between the quantity of prescribed monitoring strips
and glycaemic control. METHODS: Data were obtained from
the UK General Practice Research Database. Patients were eligi-
ble if they were identiﬁed as having type-2 diabetes, initiated
therapy with insulin or an oral agent, and had 12-month post-
initiation data. Differences in patient characteristics and number
of test strips prescribed between the insulin (n = 347) and oral
cohorts (n = 2436) were examined. Multivariate regressions ana-
lyzed the relationship between quantity of monitoring and gly-
caemic control for a subset of patients (n = 245 insulin; n = 1795
oral) with available glycosylated haemoglobin (HbA1c) data.
RESULTS: During the 12-month post-initiation period, patients
in the insulin cohort were prescribed approximately twice as
many test strips compared to those patients in the oral medica-
tion cohort. Multivariate regression revealed that individuals
who initiated therapy with insulin and were prescribed enough
test strips to test at least once per day in the six months prior to
the test date had, on average, a 0.65% lower HbA1c value (p =
0.02) compared to the HbA1c values for individuals who were
prescribed fewer test strips. In contrast there was no signiﬁcant
relationship between HbA1c levels and quantity of test strips
prescribed for individuals who initiated therapy with oral antidi-
abetic agents. CONCLUSIONS: Results indicate signiﬁcant dif-
ferences in the prescription of blood glucose monitoring strips,
with patients initiated on insulin prescribed almost twice as
many test strips compared to patients initiated on oral agents.
The greater number of blood glucose test strips prescribed was
associated with lower HbA1c values for insulin patients only.
Physicians may therefore wish to encourage frequent blood
glucose monitoring among patients with type-2 diabetes who are
treated with insulin.
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OBJECTIVES: Rimonabant is the ﬁrst selective CB1 blocker,
currently under clinical investigation to reduce multiple cardio-
vascular risk factors. Four phase III clinical studies (RIO trials)
demonstrated consistent signiﬁcant improvements in multiple
cardiometabolic risk factors including improvements in lipid and
glucose parameters, in addition to reductions of weight and waist
circumference. In patients with type-2 diabetes not adequately
controlled with a monotherapy, a 0.7% reduction in HbA1c
from a 7.3% HbA1c at baseline versus placebo was reported
compared to diet and exercise alone, with a 15.4% increase in
HDLc and 9% decrease in triglycerides from baseline. Approx-
imately 50% of these effects were independent from weight loss.
The objective was to predict the long-term clinical outcomes of
treatment with rimonabant in the management of cardiovascu-
lar risk in abdominally obese diabetics. METHODS: A 20-year
Markov model with a 6-month cycle-length and states repre-
senting diabetes, smoking, cardiovascular disease and death was
developed. The weight-loss and beyond-weight-loss effects of
rimonabant were modeled using the Framingham and UKPDS
risk equations. A ﬂexible time horizon of 1 to 20 years was
applied. Patient characteristics and clinical data from the Rio-
diabetes study were used. Extensive probabilistic sensitivity
analyses were carried out. RESULTS: For a cohort of 1000
patients, 1 year rimonabant treatment compared to diet and
exercise alone, prevented 15 events (stroke, MI, fatal and non
fatal; angina, TIA) over a 20-year period, resulting in 50 life
years gained. For a 2-year treatment duration, 27 events would
be avoided, resulting in 84 life years gained. CONCLUSION:
The treatment of cardiometabolic risk factors with rimonabant
in abdominally obese patients with type-2 diabetes is likely to
result in signiﬁcant long-term clinical beneﬁts.
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Diabetes Mellitus and its complications cause a high burden of
disease. Many different options for primary prevention and the
prevention of its complications exist. To support decision makers
in allocating money to different interventions in health care,
insight into their costs and health effects over time is important,
as well as the possibility to analyze the consequences of differ-
ent objectives and constraints of the decision maker. OBJEC-
TIVES: To develop a model that enables the comparison of
primary prevention with the prevention of complications in dia-
betes patients as to costs of care and health effects. This is the
ﬁrst step in the development of a budget allocation model for
diabetes. METHODS: Based on the RIVM Chronic Disease
Model, a multistate transition model was developed with states
representing individuals’ risk factor and disease status. The
model describes the relations between diabetes, its risk factors
and its macrovascular complications. A health economics
module computes outcomes in terms of intervention costs, costs
of care and composite health effects and ﬁnally cost-effectiveness
ratios. RESULTS: A set of formal equations deﬁnes the diabetes
model and a health economics module. These were implemented
in Mathematica and combined with estimates of input data, to
result in a population model, linking risk factor prevalence in the
population to incidence of diabetes, and linking risk factor
prevalence in the diabetes population to incidence of complica-
tions. CONCLUSIONS: Basing the model on the Chronic
Disease Model had the advantages of full inclusion of compet-
ing death risks in the model and easy generalizability to other
chronic diseases. The model with the health economics module
enables to compare the costs and effects of interventions on 
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different risk factors for cardiovascular complications, both in
the general population and in diabetes patients.
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OBJECTIVES: A number of diabetes models have recently been
published. They are often used to assess the cost-effectiveness of
new interventions and to generate health economic arguments
for reimbursement submissions. The majority of these models do
not account for rates of screening for important diabetes-related
microvascular (eye, renal and foot) disease, nor do they consider
the rates of use of important concomitant medications like ACE
inhibitor/angiotensin-2-receptor inhibitors, statins, or aspirin.
Our aim was to test the hypothesis that not accounting for these
important factors may substantially inﬂuence projected long-
term cost-effectiveness of new interventions. METHODS: A
published and validated diabetes model was used to project the
long-term cost-effectiveness of a hypothetical intervention that
lowered HbA1c by 0.4%-points, and which cost an additional
$500/patient/year, versus no intervention. Quality-adjusted life
years (QALY) and lifetime direct medical costs were calculated
for each treatment arm, taking into consideration: A) no screen-
ing for- and appropriate treatment of diabetes-related complica-
tions, or B) screening rates and concomitant medication use as
seen in a typical type-2 diabetes population in the US. RESULTS:
If screening rates and concomitant medication use were not con-
sidered, the hypothetical intervention was dominant to no inter-
vention, with 0.214 QALYs gained (discounted 3% annually),
and discounted lifetime direct cost savings of $165/patient.
When screening rates and concomitant medication rates were
accounted for, the intervention led to smaller improvements 
in QALYs, and increased costs, with incremental costs/QALY
gained of $34,024. CONCLUSIONS: Health economic models
of diabetes must account for the costs and clinical effects of
screening for- and appropriate treatment of important dia-
betic microvascular complications, and the costs and effects of
important concomitant medications. Failure to account for 
these factors may lead to inaccurate assessment of the cost-
effectiveness of new interventions in Type-2 diabetes patients.
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OBJECTIVES: The Economic Assessment of Glycemic control
and Long-term Effects (EAGLE) model version 2.0 simulates
long-term diabetes-related complications and related costs for
type-1 and Type-2 diabetes using equations derived from the
published results of several large interventional studies (DCCT,
WESDR, and UKPDS). To assess the model’s validity, EAGLE
was internally validated according to current guidelines.
METHODS: Following in-house testing protocols, ﬁrst-order
validation identiﬁed inconsistencies in results and corrected 
programming errors. Second-order validation involved the fol-
lowing steps: 1) Simulation sets were created in EAGLE based
on baseline data from the studies used to build the model; 2)
Simulations were run. The results obtained with EAGLE were
compared with the published event rates; and 3) Risk equations
were reﬁned if a deviation of >10% was observed between the
model-derived and published results. Patient numbers and itera-
tions were systematically changed until a ﬁnal run was per-
formed with 50,000 patients and 100 iterations. RESULTS:
Fulﬁlling a criterion for validity, the cumulative incidence per
1000 patient-years and incidence rates for all events simulated
with EAGLE fell within the range of ±10%. The difference
between published data and model results ranged from 0% 
to 9% for all patient populations after possible reﬁnements. 
For example, in Type-2 diabetes, EAGLE successfully predicted
the end-stage renal disease and fatal event rates reported in
UKPDS (deviation = 0%). The rates of severe hypoglycemia dif-
fered by 1%. The EAGLE event rates for proliferative and non-
proliferative retinopathy corresponded well with event rates
derived from the WESDR publications (deviation = 3% and 4%,
respectively). CONCLUSIONS: EAGLE consistently predicts
event rates reported by UKPDS, WESDR, and DCCT, and is thus
a valid and robust tool for the analysis of the long-term diabetes-
related complications and related costs in type-1 and Type-2 
diabetes.
PDB54
W
IT
HD
RA
W
N
